This company provides advanced manufacturing solutions for biotherapeutics, specializing in protein expression and nucleic acid synthesis. They offer the Pfenex Expression Technology platform for complex therapeutic proteins and high-efficiency Prima RNA polymerases for mRNA production. Additionally, they supply PeliCRM197, a carrier protein used in commercial conjugate vaccines and immunotherapies.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The biopharmaceutical industry faces challenges in efficiently and cost-effectively manufacturing complex biologics, including proteins, mRNA, and oligonucleotides, which can hinder the development and accessibility of next-generation therapeutics and vaccines. Traditional manufacturing methods often struggle with low yields, high costs, and difficulties in producing high-quality biologics at scale.
Solution
Primrose Bio provides manufacturing solutions for biotherapeutics and vaccines, specializing in high-efficiency production systems for complex biologics. The company leverages advanced protein expression and enzyme engineering technologies to overcome manufacturing challenges and accelerate the development of innovative therapeutics. Primrose Bio's offerings include the Pfenex Expression Technology for complex protein expression, Prima RNApols for enhanced mRNA manufacturing, and enzymatic oligonucleotide synthesis (EOS) for cost-effective DNA and RNA oligonucleotide production. These technologies aim to improve yields, reduce costs, and deliver higher-quality biologics for research, therapeutic, and vaccine applications.
Target Audience
Primrose Bio serves biopharmaceutical companies, vaccine manufacturers, and research institutions seeking to improve the manufacturing of complex proteins, mRNA, and oligonucleotides for therapeutic and vaccine development.
Features
- **Pfenex Expression Technology:** A _Pseudomonas fluorescens_ based platform for complex protein expression, enabling production of antibody derivatives, recombinant therapeutic enzymes, and vaccine antigens with high yields.
- **Prima RNApols:** RNA polymerases designed to improve yields, reduce costs, and deliver higher quality mRNA drug substance, with emphasis on long-template applications and flexibility in incorporating 5’ caps.
- **PeliCRM197:** A CRM197 carrier protein produced using Pfenex Expression Technology, used in conjugate vaccines, immunotherapies, and other novel applications.
- **Function Generator:** A platform and molecular evolution toolbox for protein, enzyme, and cellular functionality enhancements.
- **Enzymatic Oligonucleotide Synthesis (EOS):** An enzymatic process for manufacturing DNA and RNA oligonucleotides, offering a cost-effective and sustainable alternative to traditional chemical synthesis.
- **Pfast Feasibility Program:** A program to assess the feasibility of producing specific proteins using the Pfenex Expression Technology.
- State-of-the-art facility designed to scale from initial clone to GMP transfer, featuring advanced analytical tools for comprehensive protein analysis during product development, including fermentation capabilities extending up to 100L.